Literature DB >> 12496518

Intraindividual comparison of gadopentetate dimeglumine, gadobenate dimeglumine, and gadobutrol for pelvic 3D magnetic resonance angiography.

Christoph U Herborn1, Thomas C Lauenstein, Stefan G Ruehm, Silke Bosk, Jörg F Debatin, Mathias Goyen.   

Abstract

RATIONALE AND
OBJECTIVES: To compare the effect on image quality of a 1.0 mol/L gadolinium chelate with that of two 0.5 mol/L gadolinium compounds.
MATERIALS AND METHODS: Five healthy volunteers underwent a mono-station 3D MRA exam (Siemens SONATA, Erlangen, Germany) four times using four separate gadolinium preparations. All subjects first received a fixed volume of undiluted gadobutrol (1 mol/L), which corresponded to a dose between 0.1 and 0.15 mmol/kg body weight. This gadobutrol dosage was then diluted with saline into twice the volume and administered as a bolus at twice the injection rate. For Gd-DTPA and Gd BOPTA, because these contrast agents are 0.5 mol/L preparations, the volume and flow rate were doubled to match diluted gadobutrol volume and concentration. Quantitative and qualitative analysis of the angiographic data sets was performed on nine arterial segments.
RESULTS: Image quality was rated diagnostic for all image data sets without statistically significant differences between any of the compounds (P > 0.3). Quantitative measurements of Gd BOPTA (SNR: 81.15; CNR: 68.91) and both standard and diluted forms of gadobutrol (SNR: 84.33; CNR: 71.62; SNR(diluted): 79,23; CNR(diluted): 66.26) yielded significantly higher results (P < 0.02) in comparison with Gd-DTPA (SNR: 49.55; CNR: 38.24). The difference between either form of gadobutrol and Gd BOPTA was not shown to be statistically significant (P > 0.3), whereas both the SNR and CNR of standard gadobutrol were significantly higher than diluted gadobutrol.
CONCLUSION: Gadobutrol- and Gd BOPTA-MRA exams lead to improved delineation of the pelvic arterial morphology compared with MRA exams performed with Gd-DTPA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12496518     DOI: 10.1097/00004424-200301000-00004

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  14 in total

1.  [Significance of MR angiography for imaging diagnostics of carotid artery diseases].

Authors:  L Schuster; T Hauser; M Essig
Journal:  Radiologe       Date:  2010-07       Impact factor: 0.635

Review 2.  MRA of abdominal vessels: technical advances.

Authors:  Henrik J Michaely; Olaf Dietrich; Kambiz Nael; Sabine Weckbach; Maximilian F Reiser; Stefan O Schoenberg
Journal:  Eur Radiol       Date:  2006-05-24       Impact factor: 5.315

3.  Assessment of the abdominal aorta and its visceral branches by contrast-enhanced dynamic volumetric hepatic parallel magnetic resonance imaging: feasibility, reliability and accuracy.

Authors:  Robert Werder; Daniel Nanz; Amelie M Lutz; Dominik Weishaupt; Lucas McCormack; Burkhardt Seifert; Borut Marincek; Jürgen K Willmann
Journal:  Eur Radiol       Date:  2006-09-01       Impact factor: 5.315

4.  Prospective intraindividual comparison of gadoterate and gadobutrol for cervical and intracranial contrast-enhanced magnetic resonance angiography.

Authors:  Philip Hoelter; Stefan Lang; Marina Weibart; Manuel Schmidt; Michael F X Knott; Tobias Engelhorn; Marco Essig; Stephan Kloska; Arnd Doerfler
Journal:  Neuroradiology       Date:  2017-09-14       Impact factor: 2.804

Review 5.  High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review.

Authors:  Frederik L Giesel; Amit Mehndiratta; Marco Essig
Journal:  Eur Radiol       Date:  2010-06-23       Impact factor: 5.315

6.  Assessment of the kidneys: magnetic resonance angiography, perfusion and diffusion.

Authors:  Ulrike I Attenberger; John N Morelli; Stefan O Schoenberg; Henrik J Michaely
Journal:  J Cardiovasc Magn Reson       Date:  2011-11-15       Impact factor: 5.364

7.  Contrast-enhanced magnetic resonance angiography (MRA): evaluation of three different contrast agents at two different doses (0.05 and 0.1 mmol/kg) in pigs at 1.5 Tesla.

Authors:  M Voth; Henrik J Michaely; C Schwenke; B Vos; H Pietsch
Journal:  Eur Radiol       Date:  2010-09-01       Impact factor: 5.315

8.  Three-dimensional contrast-enhanced magnetic-resonance angiography of the renal arteries: interindividual comparison of 0.2 mmol/kg gadobutrol at 1.5 T and 0.1 mmol/kg gadobenate dimeglumine at 3.0 T.

Authors:  Ulrike I Attenberger; Henrik J Michaely; Bernd J Wintersperger; Steven P Sourbron; Klaus-Peter Lodemann; Maximilian F Reiser; Stefan O Schoenberg
Journal:  Eur Radiol       Date:  2008-02-16       Impact factor: 5.315

9.  Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: results of a multicenter, single-blind, interindividual, randomized clinical phase III trial.

Authors:  Bernd Tombach; Klaus Bohndorf; Wolfgang Brodtrager; Claus D Claussen; Christoph Düber; Michael Galanski; Eckhardt Grabbe; Giacomo Gortenuti; Michael Kuhn; Walter Gross-Fengels; Renate Hammerstingl; Brigitte Happel; Gertraud Heinz-Peer; Gregor Jung; Thomas Kittner; Roberto Lagalla; Philipp Lengsfeld; Reinhard Loose; Raymond H G Oyen; Pietro Pavlica; Christiane Pering; Roberto Pozzi-Mucelli; Thorsten Persigehl; Peter Reimer; Nomdo S Renken; Götz M Richter; Ernst J Rummeny; Fritz Schäfer; Malgorzata Szczerbo-Trojanowska; Andrzej Urbanik; Thomas J Vogl; Paul Hajek
Journal:  Eur Radiol       Date:  2008-07-08       Impact factor: 5.315

10.  Revisiting classic MRI findings of venous malformations: Changes in protocols may lead to potential misdiagnosis.

Authors:  M D Alexander; N Hughes; D L Cooke; C P Hess; I J Frieden; A S Phelps; C F Dowd
Journal:  Neuroradiol J       Date:  2018-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.